Healthcare / Medical Instruments & SuppliesStockholm
$0.00
+0.00 (+5.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-12.5M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$30M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-959.5%
↓Gross Margin
90.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-71.4%
FCF CAGR
—
FCF margin
-2.0%
FCF / Net income
0.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48165.0 · net income $-3.2M · FCF $-958.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $48165.00 | $48165.00 | $4.8M | $3.6M | $2.1M |
| Net Income | $-3.2M | $-3.2M | $-14.8M | $-14.3M | $-15.4M |
| EBITDA | $-3.1M | $-3.1M | $-13.3M | $-12.9M | $-14.8M |
| EPS | — | — | -0.01 | -0.01 | -0.03 |
| Gross Margin | 90.0% | 90.0% | 25.6% | 55.9% | 27.0% |
| Operating Margin | -6637.3% | -6637.3% | -256.1% | -390.0% | -709.1% |
| Net Margin | -6627.7% | -6627.7% | -308.5% | -392.9% | -745.7% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.71 | 0.22 | — |
| Cash Flow | |||||
| Free Cash Flow | $-958.00 | $-958.00 | $-12.5M | $-14.0M | $-17.4M |
| Returns | |||||
| ROE | -959.5% | -959.5% | -348.8% | -103.6% | -101.0% |
| Valuation | |||||
| P/B | 91.59 | 91.59 | 3.01 | 2.35 | 2.77 |
| Growth & Yield | |||||
| Revenue Growth | -99.0% | -99.0% | 32.5% | 75.5% | — |
| EPS Growth | — | — | 40.7% | 51.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → n/d
Residual
+10.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.